Simvastatin: a review (Q34372227)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Simvastatin: a review	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

Simvastatin: a review (English)

1 reference

Europe PubMed Central

1 August 2017

1 reference

based on heuristic

inferred from title

author name string

Terje R Pedersen

1

1 reference

Europe PubMed Central

1 August 2017

Jonathan A Tobert

2

1 reference

Europe PubMed Central

1 August 2017

language of work or name

0 references

publication date

1 December 2004

1 reference

Europe PubMed Central

1 August 2017

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

1 August 2017

5

1 reference

Europe PubMed Central

1 August 2017

2583-2596

1 reference

Europe PubMed Central

1 August 2017

12

1 reference

Europe PubMed Central

1 August 2017

Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

A receptor-mediated pathway for cholesterol homeostasis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Regulation of cholesterol synthesis in rat adrenal gland through coordinate control of 3-hydroxy-3-methylglutaryl coenzyme A synthase and reductase activities

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Effect of morning versus evening intake of simvastatin on the serum cholesterol level in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Taking simvastatin in the morning compared with in the evening: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

The liver and lovastatin

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Risk for myopathy with statin therapy in high-risk patients.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Effects of fibrates on metabolism of statins in human hepatocytes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Nicotinic acid-associated myopathy: a report of three cases

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S).

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2583

21 January 2018

Identifiers

10.1517/14656566.5.12.2583

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34372227&oldid=1965424463"